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Mast cells are highly granulated cells  of  the  immune  system  that  upon  stimulation
release  a  number  of  inflammatory  mediators  including  heparin  and/or  chondroitin
sulphate  (CS)  proteoglycan  (PG)  and  various  heparin-binding  proteases  such  as
tryptase,  chymase  and  carboxypeptidase  A  (CPA).  Mast  cell  CPA  is  a  zinc-
metalloexopeptidase, cleaving substrates  with carboxyl-terminal  aliphatic  or aromatic
amino acids. In this thesis,  the storage  and activation  of CPA was investigated,  using
bone marrow derived mast cells (BMMCs) from mice lacking heparin, either due to loss
of the gene coding for the heparin biosynthesis enzyme, NDST-2, or the gene coding
for the PG core protein serglycin (SG).
We found that BMMCs from NDST-2
-/- mice that  thus  lack heparin, but  produce  CS,
lack the chymase, mMCP-5 and mature CPA. Interestingly, the  pro-form,  but  not  the
active form of CPA could be detected in the heparin-deficient cells, indicating a role for
heparin  in  the  processing  of  CPA.  Furthermore,  we  have  shown  that  the  cysteine
proteases, cathepsins C and S, are not involved in processing  CPA, but  rather that  lack
of cathepsin C or S cause increased  levels  of  CPA as  well  as  mMCP-5. In  addition,
neither cathepsins B nor L influence CPA  processing  at  all,  but  instead,  an  aspartic
protease, cathepsin E, plays a role in processing  pro-CPA. Further, these studies  led to
the novel finding that cathepsin  E is located  inside  the mast cell granules,  where it is
stored in complex with heparin.
The  activation  of  mast  cells,  which  ultimately  leads  to  degranulation,  has  been
studied in detail; however, the process where  mast  cell  granules  are formed  has  not
gained as much attention. We addressed this issue by the use  of  BMMCs from  mice
lacking SG. Here, we present evidence that secretory granules are formed independently
of SG PG but that SG mediates  selective  condensation  of certain granule  constituents,
while others are independent of SG. Mast cell proteases are  correctly  sorted  into  the
granules but are subsequently degraded, exocytosed or remain unprocessed when  SG is
absent. These results indicate a model in which selected granule constituents  are sorted
into granules by SG-mediated retention.
Keywords: mast cell mediator, protease, proteoglycan, proteolytic activation,  granule
formation, cathepsin
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DPPI dipeptidyl peptidase I
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ER endoplasmatic reticulum
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HDC histidine decarboxylase
Ig immunoglobulin
IL interleukin
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MS multiple sclerosis
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TLR toll-like receptor
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Introduction
The immune system
Everyday we encounter bacteria, viruses and other  pathogens.  The  skin  and
mucosal tissues act as a first barrier, but  many pathogens still  enter our body.
However, most infections in  normal individuals are short-lived and leave little
permanent damage. This is due to the immune system, which combats infectious
agents. All immune responses involve, firstly, recognition of the pathogen, and
secondly, mounting a reaction against it to eliminate it. There are two  types of
immune responses: innate and adaptive. The adaptive response is highly specific
for a particular pathogen and improves with  each successive encounter with  the
same pathogen whereas the innate immune response does not  alter on  repeated
exposure to a given infectious agent.
A number of cells and mediators released by them are involved in  immune
responses. Leukocytes are the main group of immunological cells consisting of the
phagocytic cells (monocytes, macrophages and polynuclear neutrophils) and the
lymphocytes (T lymphocytes and B lymphocytes). Phagocytes have a non-specific
recognition system  and  are the  first  line  of  defence in  the  innate  responses.
Lymphocytes on the other hand, specifically recognize individual pathogens and
are thus involved in the adaptive immune response.  A  number  of  other  cells
mediate inflammation, the main purpose of which is to attract leukocytes and the
soluble mediators of immunity  towards a site  of infection. These cells include
platelets, basophils and mast cells.
The mast cell
Mast cells are highly granulated cells of the immune system that are especially
prominent near surfaces exposed to the environment, including the skin, airways
and gastrointestinal tract,  where they  serve as  a  first  line  of  defence against
pathogens, allergens and other environmental agents. Mast cells were discovered in
1877 (Ehrlich, 1877), and in recent decades it has become more and more evident
that the mast cell is a highly important cell that is involved in  several different
physiological and pathological conditions. The diverse roles of mast cells  and
their mediators will be reviewed and investigated in this thesis.
Mast cells arise from pluripotent haematopoietic stem cells in the bone marrow
(Kitamura et al., 1981, Sonoda, Ohno and Kitamura, 1982, Sonoda et al., 1983,
Bender, Van Epps and Stewart, 1988, Kirshenbaum et al., 1991). However, mast
cells do not ordinarily circulate in their mature form; instead, they undergo the
terminal  stages  of  their  differentiation  and/or  maturation  locally,  after  the
migration of their precursors into those vascularized tissues or serosal cavities in
which  they  ultimately  will  reside.  Specific  growth  factors  influencing  the
differentiation of mast cells include stem  cell factor (SCF),  interleukin-3 (IL-3)10
and nerve growth factor (in humans only)  (reviewed in  (Metcalfe, Baram  and
Mekori, 1997). Other mediators such as IL-4, IL-9 and IL-10 can also regulate
mast cell differentiation.
Mast cell heterogeneity
Both rodent and human mast cells display a high degree of heterogeneity based on
their granular location and contents (Galli, 1990). In rodents, two main subtypes
have been described (Table 1). The connective tissue mast cells (CTMC) are found
in the skin and peritoneal cavity and contain heparin proteoglycan, high amounts
of histamine and the proteases tryptase, chymase and carboxypeptidase A  (CPA)
whereas the mucosal mast cells (MMC) reside beneath mucosal surfaces such as
the  lamina  propria  of  the  respiratory  and  gastrointestinal  tract  and  contain
chondroitin sulphate proteoglycan and  chymase,  but  lacks  tryptase and  CPA.
Human mast cells can be similarly subdivided into two populations based on their
granular content (Irani et  al.,  1986)  (Table 1).  One  phenotype contains  only
tryptase and is termed MCT whereas the other (MCTC) contains both tryptase and
chymase as well as cathepsin G and CPA. MCTC are found in human dermis and
subepithelial sites such as in airway and gastrointestinal submucosa, whereas the
MCT subset is located predominantly in airway and gastrointestinal sites  and in
alveolar tissue (Irani et al., 1986). It has also been proposed that the two human
mast cell phenotypes express different arrays of cytokines (Bradding et al., 1995).
Table 1. Mast cell heterogeneity in mouse and human
Mast cell granules
A prominent feature of mast cells is their electron  dense  secretory granules
containing the different preformed mast cell mediators. Mast cells were first
described by Ehrlich in 1877 (Ehrlich, 1877), when he detected cells in  various
organs of several animal  species  with  densely  packed  (overfed) cytoplasmic
granules and therefore named them “mästzellen”, from the German word “mäst”,
referring to feeding.
         Mouse           Human
CTMC MMC MCT MCTC
Proteoglycan Heparin CS Heparin &
CS
Heparin &
CS
Tryptase mMCP-6,
mMCP-7
- + +
Chymase mMCP-4,
mMCP-5
mMCP-1,
mMCP-2
- +
CPA + - - +11
Granule formation
Even  though  the  process  and  signalling  pathways  leading  to  mast  cell
degranulation have been intensely investigated (reviewed in  (Blank and Rivera,
2004),  the mechanism by which the mast cell granules are formed is still largely
unknown.
Every existing cell contains a secretory pathway to  deliver newly synthesised
proteins to the cell surface, called the constitutive pathway. Secretory cells, like
mast  cells,  also  support  another  pathway  known  as  the  regulated  secretory
pathway, where proteins destined for the secretory granules are sorted. Most
secretory proteins are translated on  ribosomes bound to  the ER  (endoplasmatic
reticulum) and following the removal of the signal peptide, are transported to the
Golgi in vesicles, where they are further processed while they pass the cis- and
medial-cisterns until they finally reach the trans-Golgi network (TGN). In a
general view, secretory granules (in endocrine, neuroendocrine end exocrine cells,
such as mast cells) form in the TGN and are  classified initially  as  immature
secretory granules (ISGs) (Tooze, Martens and Huttner, 2001) . Several subsequent
events convert ISGs to mature secretory granules (MSGs). These changes include a
change in size and modification of the composition of the membrane and content
of the secretory granule. The TGN has been suggested to  be the location where
proteins are sorted to  their final destination. However, whereas the mannose-6-
phospate receptor has been shown to mediate targeting of lysosomal proteins from
the TGN (Kornfeld and Mellman, 1989), no such sorting receptor has  been
identified for mast cell secretory granule proteins.
In the past 20 years, two different hypotheses have  emerged to  explain  the
selection of proteins for storage in secretory granules (Arvan and Castle,  1998).
Importantly, these models are not mutually exclusive. In the sorting-for-entry
model, the TGN is  seen as the location where sorting takes place (Figure 1a).
Regulatory secreted proteins aggregate in the TGN, bind to a sorting receptor and
are thus actively separated from proteins that are constitutively secreted. In the
sorting-by-retention model on the other hand, proteins are packed into ISGs in an
unsorted manner and regulated secretory proteins are retained in  the ISG,  where
they aggregate and bind to a receptor similar to the sorting-for-entry model, while
other proteins bud off from the ISG in vesicles in which their granule content is
gradually refined (Figure 1B). Which of these apply to mast cell granule formation
is not known, but in a recent study it was shown that serglycin proteoglycan is
necessary for correct storage of mast cell proteases in mast cell granules (Abrink,
Grujic and Pejler, 2004)12
Figure 1. The two proposed models for granular sorting. TGN = trans-Golgi  network,
ISG  =  immature  secretory  granule,  MSG  =  mature  secretory  granule.
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Activation/degranulation
When  mast  cell  granules  degranulate  upon  activation,  their  inflammatory
mediators are released into the extracellular milieu
Activation may occur by various mechanisms, including antigen-mediated cross
linking of surface-associated IgE or IgG and exposure to  complement factors as
well as bacterial components, neuropeptides and calcium ionophores (Figure 2).
Figure 2. Different ways of activating mast cells. For details, see the text.
IgE-mediated activation
The classical way of activating  mast  cells,  especially in  allergic reactions, is
through their high affinity IgE receptors, FcεRI. Mast cell FcεRI is a tetrameric
protein complex (Blank et al., 1989, Ra, Jouvin and Kinet, 1989), consisting of
the IgE-binding α-subunit (Hakimi et al., 1990, Blank, Ra and Kinet, 1991), a
single  signal-amplifying  membrane-tetraspanning  β-subunit  as  well  as  a
homodimeric disulphide-linked γ-subunit  (Perez-Montfort, Kinet  and  Metzger,
1983) that provides the signalling ability of the receptor.  
IgE
IgG
Complement
C3a & C5a
LPS
PGN
Zymosan
dsRNA
Neuropeptides
T-cell
ICAM-1
Compound
48/80
Calcium 
ionophore
FcεRI
FcγRIII
C3aR
C5aR
TLRs
LFA-1
Antigen14
When an antigen enters the body, it may provoke IgE production.  The  IgE
molecules bind tightly to FcεRI on the mast cell surface and the next time  the
same antigen enters it will cross-link IgE on the mast cell surface. Cross-linking
brings the receptors into  position  to  initiate intracellular signalling (Blank and
Rivera,  2004),  leading  to  mast  cell  degranulation and  release of  mast  cell
mediators.
IgE-independent  mechanisms
IgG
In addition to IgE-dependent activation, mast cells can also be activated through
the low-affinity IgG receptor  FcγRIII,  where  aggregation of  the  receptor is
followed by mast cell adhesion, degranulation and an increase in tumour necrosis
factor-α (TNF-α) synthesis (Katz et al., 1992, Latour et al., 1992).
Complement
Is has long been known that complement components C3a and C5a (also called
anaphylatoxins) can activate mast  cells  (Johnson,  Hugli  and  Muller-Eberhard,
1975). The complement system is involved in a number of processes contributing
to host  defence and/or inflammation (Muller-Eberhard, 1988). Rodent CTMCs,
but not MMCs express receptors binding complement-derived peptides C3a and
C5a and thus is the only rodent mast cell subtype that can be activated through the
complement system (Mousli et al., 1994).
Human mast cells display differential expression of the C5a receptor (C5aR) but
do not express the receptors for C3-derived fragments such as CR1,  CR2,  CR3
and CR4 (Fureder et al., 1995). However, bone marrow mast cells from patients
with systemic mastocytosis have high levels of CR1, CR4 as well as C5a receptor
(Nunez-Lopez et al., 2003), indicating a mechanism for up-regulation  of  these
receptors.
Toll-like receptors
Mast cells can also be activated by  different bacterial components through their
interactions with toll-like receptors (TLRs) expressed on the mast cell  surface.
TLRs are a highly conserved family of pattern recognition receptors that are type I
transmembrane proteins with an extracellular domain consisting of  leucine-rich
repeats and an intracellular domain with homology to the IL-1 receptor, called the
Toll/IL-1R domain (Medzhitov, Preston-Hurlburt and Janeway, 1997).
Eleven different TLRs (TLR1-11) have been identified in mammalian systems
(Rock et al., 1998, Takeuchi et al., 1999, Du et al., 2000, Chuang and Ulevitch,
2001, Zhang et al., 2004) and it has been shown that mast cells express TLR2,
TLR4, TLR6 and TLR8 (Supajatura et al., 2001). However, a recent study  also
indicates the presence of TLR3 on mast cells (Kulka et al., 2004). Activators of
TLRs include lipopolysaccharide (LPS) (TLR2 and TLR4), peptidoglycan (PGN),15
(TLR2 and TLR6) and zymosan (TLR2) as well as other bacterial components and
viral dsRNA (TLR3) (Aliprantis et al., 1999, Chow et al., 1999, Takeuchi et al.,
2001,  Kulka et al.,  2004).  The  natural  activator  of  TLR8  remains  to  be
discovered.  Binding of these activators to TLRs ultimately leads to  expression
and release of cytokines, leukotrienes and prostaglandins, usually without causing
degranulation of the mast cell (Poltorak et al., 1998, Chow et al., 1999, Qureshi
et al., 1999, Supajatura et al., 2001, Takeuchi et al., 2001, Kulka et al., 2004).
Mast cells may thus have the  potential  to  recruit other  immune  cells  to  the
infected sites by responding to various bacterial and viral components through
TLR signalling pathways.
Other mechanisms
As well  as  responding to  bacterial and  viral  components,  mast  cells  can  be
activated by neuropeptides released from neurons, beside which mast cells often
lie in proximity (Bauer and Razin, 2000). The mast cell-activating neuropeptides
include substance  P,  calcitonin  gene  regulated  peptide,  vasoactive  intestinal
peptide and neurotensin (Church et al., 1989). Mast cells can also be activated by
different types of cytokines and chemokines, such as macrophage inflammatory
protein 1α (MIP-1α) and monocyte chemoattractant-1   (Alam et al.,  1994). In
addition, activated T-cells can activate mast cells to  degranulate and  produce
cytokines,  through  the  adhesion  molecule  ICAM-1  and  its  ligand  LFA-1
(Bhattacharyya et al., 1998, Inamura et al., 1998). Other compounds that  can
directly  activate  mast  cells  include  calcium  ionophores,  compound  48/80,
morphine, codeine and synthetic  adrenocorticotropic hormone,  adenosine  and
endothelin (Metcalfe, Baram and Mekori, 1997).
In this context, it is important to emphasize that individual stimuli of mast cell
secretion can elicit distinct, through sometimes overlapping patterns of mediator
secretion. For example, although IgE and specific antigen can induce the cells to
release large quantities  of  all  classes of  mediators,  it  has  been  reported that
neuropeptides favour the release of preformed mediators (Church, el-Lati and
Caulfield, 1991), whereas LPS and other stimuli that are identified by mast cell
TLR favour the release of certain cytokines and may induce little or no release of
preformed mediators.  
Mast cell mediators
Following activation, a number of mast cell mediators are released into the
extracellular milieu of the mast cell. The vast majority of them are stored as pre-
formed, active molecules in the mast cell granules, but some, such as cytokines
and the lipid mediators are synthesized upon mast cell activation.16
De novo-synthesized mediators
Lipid medators
The lipid mediators, leukotrienes and prostaglandins, are members of the eicosaoid
family. Prostaglandins are cyclooxygenase products whereas leukotrienes (LT) are
synthesised  through  the  lipoxygenase  pathway.  Upon  activation,  mast  cells
produce the cysteinyl leukotrienes (cysLTs) LTC4,  LTD4  and  LTE4  which  are
potent inflammatory mediators that initiate and propagate a diverse  array  of
biological responses (Kanaoka and Boyce, 2004).
The cysLTs exert  their  biological  functions  through  two  G-protein coupled
receptors, CysLT1 and CysLT2 receptors (Lynch et al., 1999, Heise et al., 2000).
The biological effects of the cysLTs include bronchoconstriction (Dahlen et al.,
1980, Davidson et al., 1987) and influx of eosinophils and neutrophils into  the
lungs,  as  well  as  macrophage  infiltration,  haematopoietic  progenitor  cell
recruitment  and  eosinophil  and  mast  cell  cytokine  production  (reviewed  in
(Kanaoka and Boyce, 2004)).  Several studies have shown that inhibitors of the
cysLT-generating  pathway  (Israel  et  al.,  1996)  as  well  as  cysLT  receptor
antagonists (Altman et al., 1998) decrease symptoms in asthmatic individuals,
indicating an important role for cysLTs in acute asthma.
Prostaglandin D2 (PGD2), the main cyclooxygenase product in mast cells (Lewis
et al., 1982), has also been shown to play an important role in asthmatic responses
(Matsuoka et al., 2000). The receptor for PGD2 was knocked out, and mice lacking
this receptor did not develop asthmatic  responses in  an  OVA-induced asthma
model, indicating PGD2 and its receptors as important players in asthma.
Cytokines
Mast cells produce a broad range of cytokines, mainly of Th2 type.  It  has been
shown that activated human lung mast cells express
IL-3, IL-4, IL-5, IL-6, IL-8, IL-10 and IL-13, as well as TNF- α and GM-CSF
(Okayama et al., 1995, Ishizuka et al., 1999b, Ishizuka et al., 1999a, Kobayashi,
Ishizuka and Okayama, 2000), but there is a heterogeneity of mast cells regarding
cytokine expression (Bradding et al., 1995).  The  mast  cell  cytokines  regulate
functions of inflammatory cells, giving the mast cell an important role in the
course of pathologic inflammation.
Preformed mediators
Histamine
Perhaps the most well-known mast cell mediator is histamine, a biogenic peptide
that is  formed after decarboxylation of  histidine,  a  reaction catalyzed by  the
enzyme L-histidine decarboxylase (HDC). Histamine is found in several different
cell types throughout the body, but the main sources are mast  cells (Riley and
West, 1952) and basophils (Ishizaka et al., 1972) where it is stored as a preformed
mediator  in  the  secretory  granules.  Histamine  exerts  its  functions  through17
histamine receptors, H1-H4 (MacGlashan, 2003). H1 and H2 are widely spread
whereas H3 is  restricted to  the  brain.  H4  is  found  in  the  intestines  and  in
haematopoietic cells. All of the histamine receptors are G-protein coupled receptors
and their differential expression on almost all cells in the body makes the cellular
response towards histamine highly diverse. However, one of the  most  studied
roles of histamine is in allergic disease, where the interaction of histamine with
the histamine H1-receptor mediates the classical allergic effects, including vascular
permeability and  smooth  muscle  contraction as  well  as  sneezing and  itching
(Bachert, 2002).
To study the biological role of histamine  the  HDC  gene  was  knocked out
(Ohtsu et al., 2001). HDC-deficient mice, kept on a histidine-free diet  lack
histamine in all organs except for the brain. Interestingly, mast  cell numbers in
these mice are significantly decreased and their  granular  content  is  reduced.
However, this is not only due to the lack of histamine in the mast cell granules,
but the levels of the mast cell proteases mMCP-4, mMCP-5 and CPA as well as
heparin PG are also reduced. Possibly, the lack of histamine disturbs the normal
electrostatic balance in  the mast  cell granules, causing the disturbed storage of
granule constituents. The HDC-deficient mice have been used in several studies to
show the biological effects of histamine, such  as  angiogenesis (Ghosh  et  al.,
2002), gastric acid secretion (Tanaka et al., 2002)  as  well  as  gastric mucosal
morphology (Nakamura et al., 2004). In  addition,  Helicobacter pylori-induced
gastritis (Klausz et al.,  2004)  and  scratching behaviour in  mice  with  contact
dermatitis (Seike et al., 2005) have been shown to be dependent on histamine.
Proteoglycans
One major constituent of the mast cell granules is the highly negatively charged
proteoglycans (PGs). A PG is any glycoprotein that consists of a protein core and
has glycosaminoglycan (GAG) side chains. GAGs are polysaccharides that have a
simple repeating disaccharide unit and are highly anionic in nature because of the
presence of many sulphate and carboxyl groups. There are several types of PGs,
regarding the protein core as  well  as  the  GAG  chain.  However, it  has  been
suggested that the PG core protein expressed by mast cells is exclusively of the
serglycin (SG) type (Stevens et al., 1988a, Kjellen et al., 1989), even though the
SG core protein can have different GAG chains attached to it.
Murine CTMCs express only PGs with heparin side chains (Yurt, Leid and
Austen, 1977), whereas MMCs  express side chains of the chondroitin sulphate
(CS) type (Enerback L,  1985). In contrast, human mast  cells can contain both
GAG types in the same mast cell type (Stevens et al., 1988b). The CS side chains
are usually of the CS-E type (Razin et al., 1982, Enerback L, 1985), although CS-
B (Seldin, Austen and Stevens, 1985) and CS-D (Davidson et al., 1990) also have
been reported in certain subsets of mast cells.
Both heparin and CS consists of repeating  disaccharide units  with  different
degrees of modifications. The synthesis of heparin and CS chains is initiated with18
a linker region, consisting of xylose, galactose,  galactose and  glucuronic acid
attached to a serine residue in the core protein (Prydz and Dalen, 2000) (Figure 3).
The GAG is then elongated by the addition of repeating disaccharide units. In the
case of heparin, they consist of N-acetyl-glucosamine and glucoronic acid whereas
in CS the disaccharide unit is made up by N-acetyl-galactosamine and glucuronic
acid. Subsequent modification steps shape the final structure of the GAG-chains.
In heparin, the most highly sulphated GAG, a key modification step is  the N-
deacetylation/N-sulphation  of  N-acetyl  glucosamine  residues.  This  reaction,
catalyzed by the bifunctional enzyme N-deacetylase/N-sulphotransferase (NDST),
is the first step in the process that finally renders the fully sulphated heparin chain.
Subsequent modifications include C5 epimerization of GlcA to IdoA, and variable
O-sulphations at C2 of IdoA and GlcA, at C6 of GlcNAc and GlcNS units,  and
occasionally at C3 of GlcN residues.
Figure 3. A general scheme for the synthesis of heparin and chondroitin sulphate
Four  isoforms  of  the  key  enzyme  family  of  NDSTs  have  been  identified
(Hashimoto et al., 1992, Eriksson et al., 1994, Orellana et al., 1994, Aikawa et
al., 2001). Out of these, CTMCs express predominantly NDST-2. By  targeting
the gene for this enzyme, mast cells devoid of sulphated heparin were generated
(Forsberg et al., 1999, Humphries et al., 1999). Using this approach, several of
the functions of the mast cell-specific PG heparin could be investigated.
CTMCs from mice lacking NDST-2 lack chymase, tryptase and CPA  in  their
granules indicating a role for heparin in the storage of mast  cell  proteases.
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Furthermore, heparin was shown to  be necessary for the biological function of
some of the proteases. For example, the degradation of fibronectin by  chymase
was shown to be dependent on heparin (Tchougounova et al., 2001)  and  a
chymase-heparin  PG  complex  may  modulate  extravascular  coagulation
(Tchougounova and Pejler, 2001). Here, heparin probably works as an attractant
for  chymase  substrates,  which  in  many  cases  has  heparin  binding  motifs.
Furthermore, tryptase is  dependent on  heparin for  formation of  enzymatically
active tetramers (Hallgren et al., 2000).
However, the targeting of NDST-2 affected only CTMCs since MMCs contain
CS PG. Therefore, NDST-2 was not a perfect tool for studying the role of mast
cell PGs in general. To address this issue, mice lacking the core protein, SG, were
generated (Abrink, Grujic and Pejler, 2004). These mice show a complete lack of
mast cell PGs, indicating that SG is  indeed the only  core protein in  mast  cell
PGs. Moreover, mast cells from the SG knock out  had a defect in  storage and
processing of the mast cell proteases similar to the NDST-2-deficient mast cells.
However, the  mechanisms behind  these  granular abnormalities have  not  been
investigated in detail.
Proteases
In terms of mass and molarity, proteases that are enzymatically active at neutral
pH are the major protein constituents exocytosed from activated mast cells. Up to
35 % of the total protein content in mast cell granules are proteases (Schwartz et
al., 1987). Tryptases, chymases and carboxypeptidase A (CPA) represent the three
major families of proteases stored in the secretory granules of mast  cells where
chymase and tryptase are serine proteases with endopeptidase activity,  whereas
CPA is a metalloprotease with exopeptidase activity. In addition, the serine
protease cathepsin G has also been reported in certain human MCTC (Meier et al.,
1985, Schechter et al., 1990).
Chymase
Chymases are serine proteases  with  chymotrypsin-like  substrate  specificity,
cleaving substrates downstream from aromatic amino acids (Powers et al., 1985).
Chymases were first identified and localized in mast cell granules in 1959 (Benditt
and Arase, 1959), and they can be  divided  into  two  separate groups,  the  α-
chymases and the β-chymases (Chandrasekharan et  al.,  1996).  In  humans,  α-
chymase alone is expressed, whereas even though the β-chymases are ancient, they
seem to exist only in rodents where, in mice, they are known as mouse mast cell
proteases (mMCP) –1, -2, -4, and –9. In mice, as in humans, α-chymase  exists
alone, and is called mMCP-5.  Not  all  chymases are expressed in  all  mast  cell
subclasses. MMCs in mice express mMCP-1 and -2 whereas CTMCs have been
shown to express mMCP-4 and –5. In humans, only the MCTC express chymase.
Chymase is stored as an active enzyme in  the mast  cell granules in  complex
with heparin. Activation of pro-chymase occurs by the removal of a two-residue20
propeptide by dipeptidyl pepdidase I  (DPPI,  also  known  as  cathepsin C),  as
shown from experiments using DPPI knockout mice (Wolters et al., 2001). After
degranulation,  the  chymase  remains  in  a  tight  complex  with  heparin  PG,
protecting chymase from protease inhibitors (Pejler and Berg, 1995) as well as
increasing the enzymatic activity of chymase (Pejler and Sadler, 1999). It has been
suggested that the negatively charged heparin brings positively charged substrates
close to the chymase and  reduces the  level  of  electrostatic repulsion  between
chymase  and  its  positively  charged  substrates  (Pejler  and  Sadler,  1999,
Tchougounova  and  Pejler,  2001).   Functions  ascribed  to  mast  cell  chymase
include attraction of neutrophils and eosinophils (He and Walls, 1998, Watanabe,
Miura and Fukuda, 2002)  and  extracellular matrix  remodelling by  fibronectin
degradation (Tchougounova et al., 2001) and matrix  metalloprotease activation
(Tchougounova  et  al.,  2005)  as  well  as  TIMP  (tissue  inhibitor  of
metalloproteinases) inactivation (Frank et al., 2001). Furthermore, chymase may
be involved in extravascular coagulation and fibrinolysis, where it can degrade
thrombin as well as plasmin (Tchougounova and  Pejler,  2001)  .  In  addition,
chymase seems to play a role in the extravascular processing of angiotensin I to
angiotensin II (Chandrasekharan et al., 1996).
Most of these findings are results of in  vitro investigations. However, knock
outs for two of the β-chymases, mMCP-1  (Knight et al.,  2000) and mMCP-4
(Tchougounova, Pejler and Abrink, 2003), and the α-chymase mMCP-5 (Abonia
et al., 2005) have recently been generated, allowing experiments that have verified
some of the in vitro-data. Because mMCP-5 is an α-chymase it was thought to be
the homologue of human chymase. However, recent studies have indicated that
mMCP-5  and  its  rat  counterpart,  rMCP-5,  have  elastase-like,  rather  than
chymotrypsin-like substrate specificities (Kunori et al., 2002, Karlson et al.,
2003). Because of these findings, mMCP-4 was chosen as the next candidate for
being the human chymase counterpart and indeed, the deletion  of  mMCP-4
showed that this chymase accounted for the major chymotrypsin-like activity in
the peritoneum and ear tissue in mice (Tchougounova, Pejler and Abrink, 2003).
Furthermore, mMCP-4 was also proven to play an important role in angiotensin-
processing, together with CPA (Lundequist et  al.,  2004).  The  knockout  of
mMCP-1 has also indicated the involvement of this α-chymase in  expulsion of
the parasite, Trichinella spiralis (Knight et al., 2000).
Tryptase
The other mast cell serine protease has tryptic-like substrate specificity and is thus
called tryptase. There are two main types of human mast cell tryptases: α-tryptase
and β-tryptase. There is  approximately 90% sequence identity between the two
types. β-tryptases are further classified into βI-, βII- and βIII-tryptases (Miller,
Moxley and Schwartz, 1990, Vanderslice et al., 1990), and the α-tryptases into
αI- and αII-tryptases (Miller, Westin and Schwartz, 1989, Pallaoro et al., 1999).
Moreover, other members of the tryptase family include γ-tryptase, which may be
anchored to the plasma membrane (Caughey et al., 2000) and δ-tryptase (Wang et
al., 2002). β-tryptases appear to be the main type expressed in humans, whereas21
the α-tryptases have an amino acid  substitution  rendering them  constitutively
secreted. Furthermore, the α-tryptases have no or little enzymatic activity  and
about 29% of the human population lack α-tryptase, without any obvious defects
(Soto et al., 2002). In mice, four mast cell tryptases have been identified to date.
These are mMCP-6, mMCP-7, the newly found mouse transmembrane tryptase
and mMCP-11. mMCP-6 is the mouse tryptase most closely related to human β-
tryptase, with 78% sequence  identity.  In  mice,  tryptase is  only  expressed in
CTMC,  whereas  both  types  of  human  mast  cells  (MCT  and  MCTC)  contain
tryptase.
Tryptases, like chymases, are stored in the mast cell granules as active enzymes.
Active tryptase is a homotetramer with the  active sites  facing a  central pore,
stabilized by heparin (Schwartz and Bradford, 1986). Activation of tryptase may
occur in two steps where the first step is an autocatalytic cleavage into pro’tryptase
and the second is removal of an N-terminal dipeptide by  DPPI  (this  enzyme is
only partially responsible for mouse tryptase activation (Wolters et al.,  2001))
which results  in  monomeric  tryptase  (Sakai,  Ren  and  Schwartz,  1996).The
tetrameric structure of tryptase, formed and stabilized by interactions with heparin
under acidic conditions  (Hallgren et  al., 2000,  Hallgren, Lindahl  and  Pejler,
2005), gives tryptase its highly selective substrate specificity,  cleaving  only
substrates small enough to enter the central pore. Furthermore, the resistance of
tryptase to macromolecular inhibitors can also be attributed to its tetrameric
structure. However, heparin antagonists have been shown to be potent inhibitors of
tryptase (Hallgren et al., 2001, Lundequist et al., 2003), in  accordance with  its
heparin-dependent activation.
Tryptase has been shown to degrade low molecular weight peptides such as the
bronchodilators vasoactive intestinal peptide (Caughey et al.,  1988) and peptide
histidine-methionine (Tam and Caughey,  1990),  which  may  lead  to  increased
bronchial responsiveness and contribute to the involvement of tryptase in asthma.
Tryptase may also increase vascular permeability through activation of prekallikrin
and  production  of  bradykinin  from  kininogens  (Imamura  et  al.,  1996).
Furthermore, tryptase has been reported to degrade several large matrix proteins,
e.g. fibronectin, fibrinogen and collagen type VI (Lohi, Harvima and Keski-Oja,
1992, Kielty et al., 1993). However, since these proteins are too large to fit into
the central pore of tetrameric tryptase the relevance of these findings have been
questioned (Sommerhoff et al., 2000). Interestingly, later studies have indicated
the  presence  of  active  tryptase  monomers,  degrading  both  fibronectin  and
fibrinogen (Hallgren, Spillmann and Pejler, 2001, Fajardo and Pejler, 2003). The
presence of active monomers in vivo, however, remains to be demonstrated.
In addition to reacting with the substrates discussed above, tryptase stimulates
proliferation of fibroblasts (Ruoss, Hartmann and Caughey, 1991), smooth muscle
cells (Brown et al., 1995) and epithelial cells (Cairns and Walls, 1996), which
may lead to the thickening of airway walls and increased airway responsiveness, as
seen in asthmatic patients. Tryptase also has pro-inflammatory activities, e.g.  in
its function of recruiting inflammatory cells (He, Peng and Walls, 1997, Huang et
al., 1998, Huang et al., 2001).22
Carboxypeptidase A
Carboxypeptidase-activity in mast cells was first suggested in 1979  when  a
sediment of high density from rat liver mitochondria was  found  to  contain  a
carboxypeptidase activity that was shown to originate from mast cells (Haas and
Heinrich, 1979, Haas, Heinrich and Sasse, 1979). Further evidence for a mast cell
carboxypeptidase came in the  following  year,  when  a  carboxypeptidase was
purified from rat peritoneal cells (Everitt and Neurath, 1980). Further studies on
rat, human  and  mouse  mast  cell  carboxypeptidases showed  that  this  enzyme
resides in the mast cell granules in all of these species (Goldstein et al., 1987,
Serafin et al., 1987, Cole et al., 1991, Irani et al., 1991). The enzyme was found
to be very similar to bovine  pancreatic carboxypeptidases. It  has  a  molecular
weight of approximately 35 kD and resembles bovine carboxypeptidase B (CPB)
in structure and amino acid composition,  although its  enzymatic properties are
more similar to bovine carboxypeptidase A (CPA). The enzyme was thus named
mast cell CPA (Goldstein et al., 1989).
Structure and activation
In 1989, murine and human mast cell CPA were cloned, and it was shown that
they are highly homologous (Reynolds et al., 1989a, Reynolds et al., 1989b). A
few years later rat mast cell CPA was also cloned and was found to be similar to
its mouse and human counterparts (Cole et al., 1991). In bovine pancreatic CPA
and CPB, the amino acid at position 255 is  crucial for  positioning  substrate
amino acids for cleavage. Because mouse, rat and human mast cell CPA have the
hydrophobic leucine at this site, they would be expected to more closely resemble
bovine CPA (which has an isoleucine) than CPB (which has an aspartic acid) in
its substrate specificity, in agreement with the enzymatic properties  previously
reported for mast cell CPA.
Figure 4. Schematic structure of mast cell carboxypeptidase A.
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The prepro-mast cell CPA in both mouse and human is 417 amino acids long
and consists of a 15 amino acid N-terminal signal peptide and a 94  amino acid
activation peptide (Reynolds et al., 1989a, Reynolds et al., 1989b) (Figure 4).
The unusually long activation peptide is common for all CPAs and it assumes a
compact globular conformation (Aviles et al., 1982). Molecular modelling of pro-
CPA predicts the globular propeptide domain to  physically block access to  the
substrate-binding pocket and the loop connecting the propeptide with the mature
enzyme to be highly exposed (Springman, Dikov and Serafin, 1995). Furthermore,
the model predicts that the active site of mast cell proCPA is fully formed in the
zymogens, but substrate binding is blocked by the propeptide. To activate CPA
the activation peptide must be cleaved between Glu
94   -of the activation peptide
and Ile
1 (the first residue of the mature enzyme) and degraded. As discussed above,
CPA is stored in the mast cell granules as a mature enzyme, and the location of
pro-CPA to mast cell granules indicates that the processing occurs inside the mast
cell granules (Dikov et al., 1994,  Springman, Dikov and Serafin, 1995,  Rath-
Wolfson,  2001).  Studies  using  protease  inhibitors  have  implicated  cysteine-
protease activity in the process (Springman, Dikov and Serafin, 1995), however,
the precise mechanism behind the activation has not been investigated.
Localization to the proteoglycan-protein macromolecular complex
Mast cell CPA has a highly positive net charge and has an isoelectric point  of
more than 9 (Schwartz et al., 1982). This positive net charge makes CPA binding
to the highly negative heparin PGs heparin very probable. Indeed, several studies
have indicated that CPA is located to the macromolecular PG-protein complex in
mast cells (Schwartz et al., 1982, Serafin et al., 1987), to which other mast cell
proteases have also been localized (Serafin et al., 1986). Both CPA and chymase
remain  in  this  complex  even  after  degranulation and  the  presence of  such
complexes may allow both enzymes to remain in close proximity after exocytosis,
thereby inclining the likelihood of their cooperation.
Substrates and biological functions
Based on inhibition by O-phenanthroline, EDTA and 8-hydroxyquinoline mast
cell CPA is a zinc-metallopeptidase, containing a tightly bound zinc atom directly
involved in catalysis (Everitt and Neurath, 1980, Goldstein et al., 1987). Further,
it is an exopeptidase that catalyzes the hydrolysis of peptide bonds at  the  C-
terminus of peptides (Vendrell, Querol and Aviles, 2000). Both rodent and human
mast cell CPA are functionally optimal between pH  7.5  and  9.5  and  have  a
preference for cleavage of substrates that possess carboxy--terminal aliphatic or
aromatic amino acids (Everitt and Neurath, 1980,  Goldstein et al., 1987). The
neutral to basic pH optimum indicates that mast cell CPA cleaves substrates in the
extracellular milieu rather than inside the acidic mast cell granules where it is
stored.
A number of synthetic dipeptides with carboxyl-terminal aromatic residues, e.g.
Z-Ala-Phe, and the His9-Leu10 bond of angiotensin I have been shown to be good24
in vitro substrates for mast cell CPA (Everitt and Neurath, 1980, Goldstein et al.,
1987), but little is    still  known  about  its  biological  substrates.  It  has  been
suggested that mast cell CPA might catalyze the conversion of the highly potent
broncho- and vasoconstrictor LTC4 into its less potent  form, LTF4,  and thereby
represent a cellular homeostatic mechanism for eliminating the  highly  reactive
lipid mediators produced by mast cells (Reddanna et al., 2003). Another proposed
function of mast cell CPA is the degradation of apolipoprotein B of low density
lipoprotein (LDL) (Kokkonen, Vartiainen and Kovanen, 1986). In vitro studies
using isolated rat peritoneal mast cells together with CPA inhibitors and chymase
inhibitors suggested a model where chymase and CPA act in sequence, in which
chymase first cleaves peptides from the apolipoprotein B of LDL and CPA
subsequently liberates amino acids from the peptides formed. Because chymase is
an endoprotease that acts on the carboxyl side of amino acids with aromatic side
chains, and CPA is an exoprotease that removes C-terminal amino acids  with
aromatic side chains, this cooperation seems very likely. The presence of both of
these proteases in the PG-protein macromolecular complex further supports this
theory. Further support is provided by the finding that pancreatic pro-CPA forms
complexes with pancreatic serine proteases (Oppezzo et al., 1994).
Another more recent study also suggests concerted action between mast  cell
CPA and chymase. Investigations concerning the involvement of mast cells in the
degradation of the vasoactive peptide, endothelin-1 (ET-1) indicated that CPA and
chymase were involved in this process (Metsarinne  et  al.,  2002).  The  use  of
selective inhibitors as well as purified enzymes and synthetic ET-1 in an in vitro
system showed that chymase and CPA are capable of degrading ET-1. This could
represent an important role for CPA in vivo in limiting inflammatory reactions by
degradation of  ET-1. Yet another study indicates the cooperation between mast
cell CPA and chymase. Using the knock outs of the heparin-modifying enzyme,
NDST-2 and the mouse chymase mMCP-4 together with CPA-inhibitors, is was
shown that CPA cooperates with chymase to form as well as degrade angiotensin
II (Lundequist et al., 2004). In this study, an ex vivo system was used and a model
for formation and degradation of angiotensin  II  was  proposed were CPA  and
chymase closely cooperate (Figure 5).25
Figure 5. Scheme for the processing of Angiotensin I by CPA and  mMCP-4 (adapted
from Lundequist et al., 2004)
CPA knockout
These studies all support the theory that mast  cell CPA  and chymase work in
concert to degrade different substrates. However, the true biological substrate for
mast cell CPA remains to be discovered. A  step in  this  direction is  the newly
generated knockout of mast cell CPA (Feyerabend et al., 2005). These mice appear
normal and healthy and are born at the expected Mendelian ratio, indicating that
CPA is not essential for embryonic development. The peritoneal and skin  mast
cells  appear  in  normal  numbers  and  they  are  morphologically  normal.
Furthermore, passive cutaneous anaphylaxis is not affected by  CPA-deficiency,
indicating that CPA is not required for immediate mast cell responses.
Histochemical  studies  showed  that  the  CPA-deficient  mast  cells  seemed
immature.  Their  staining  properties  resemble  those  of  BMMCs,  generally
considered  as  immature  mast  cells,  indicating  that  CPA  is  important  for
maturation of mast cells. However, heparin synthesis is unaffected and there are
normal  levels  of  the  tryptase  mMCP-6  as  well  as  the  chymase  mMCP-4.
Interestingly, mast cells  from  CPA-deficient  mice  totally  lack  the  chymase
mMCP-5, even though the mRNA levels are unaffected. This further supports the
theory  that  CPA  and  chymase  work  in  concert,  and  indicate  that  they  are
dependent on each other also for storage inside the mast cell granule. The same
pattern has been found in the knock out of the chymase, mMCP-5,  where CPA
protein is absent from the mast cell granules (Stevens et al., 1996).
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This knock out of mast cell CPA is an important  tool  to  help  elucidate the
biological role of mast  cell CPA,  However, the lack of mMCP-5  in  the CPA
knockout is an important  consideration when  performing experiments on  this
knockout.
Biological functions: are mast cells “Good Guys” or “Bad
Guys”?
Mast  cells  have  mainly  been  known  for  their  involvement  in  anaphylactic
conditions such as allergy and asthma where they are thought  of as “The Bad
Guys”. However, mast cells have been described in lower orders of animals (e.g.
insects and fishes) (Hakanson et al., 1986) and this persistence through evolution
suggests a beneficial and important role for mast cells, in which they can be seen
as “The Good Guys”.
Mast cells in host defence –“Good Guys”
Mast cells reside in locations such as the gastrointestinal tract, the skin and nerve
endings, where they  line  up  as  a  first  “defence-barrier”. It  is  not  surprising,
therefore, that mast cells are important for host  defence against certain parasites
and bacteria. Infection by helminth parasites is accompanied by eosinophilia, the
production of high levels of IgE and a mast cell hyperplasia in the mucosa of the
small intestine. Studies using the mast cell-deficient mouse strain  WBB6F1/J-
Kit
W-Kit
W-v (W/Wv) which  lack  fully  functional  c-kit  (the  receptor for  SCF)
(Kitamura, Go and Hatanaka, 1978), have shown a critical effector function for
mast cells in immunity to the parasitic helminth, Trichinella spiralis (Ha, Reed
and Crowle, 1983, Alizadeh  and  Murrell,  1984).  Furthermore, using  a  strain
lacking the MMC-specific protease, mMCP-1,  it  was demonstrated that this  β-
chymase  is  involved  in  the  expulsion  of  the  parasite  (Knight  et  al.,  2000).
Investigating W/Wv mice has also revealed a role for mast cells in the expulsion of
Nippostrongulus brasiliensis (Crowle and Reed, 1981) as well as Strongyloides
venezuelensis  (Khan et al., 1993). In the case of S.  venezuelensis, the CS PG
secreted from MMCs appears to play  an  important  role  in  parasite expulsion
(Maruyama et al., 2000). However, mast cells do not appear to  be  absolutely
necessary for the parasite expulsion in  all  cases. Rather, the lack of mast  cells
appears to delay expulsion, indicating that other factors are involved in the defence
against parasites. The role  of  mast  cells  in  protozoan infections is  less  well
described, but the involvement of mast cells in Giardia lamblia (Li et al., 2004)
as well as Giardia muris (Erlich et al., 1983) infections has been described.
The binding of different bacterial components to TLRs on mast cells activates
the mast cells and stimulates a response to several different bacteria. Using mast
cell-deficient W/Wv mice, the importance of mast cells in bacterial infections has
been demonstrated (Malaviya et al., 1996). In a model of acute septic peritonitis
(cecal ligation and puncture) a critical protective role of mast cells and mast cell-
derived TNF-α was demonstrated (Echtenacher, Mannel and Hultner, 1996). TNF-27
α enhances neutrophil  recruitment during  bacterial infection (Malaviya et  al.,
1996). Moreover, other mast cell mediators such as LTB4 (Malaviya and Abraham,
2000), tryptase (Huang et al., 2001), MIP-1α, MIP-1β, MIP-2  and  IL-8  also
appear to contribute to the influx of neutrophils to sites of  bacterial infection
(Krishnaswamy et al., 2001). In addition to initiating  site-specific inflammation
through the recruitment of neutrophils, mast cells can  themselves phagocytose
bacteria (Malaviya et al., 1994, Arock et al., 1998), although this is probably not
their main role in bacterial clearance.
In addition to host defence, mast cells have been shown to be involved in tissue
remodelling activities, for example wound healing. Histamine released from mast
cells increases fibroblast migration and proliferation (Kupietzky and Levi-Schaffer,
1996), and histamine, as well as other cytokines and growth factors released from
mast cells, can initiate or modulate angiogenesis, another important process in
wound healing (Ribatti et al., 2004). However, this angiogenic function of mast
cells may also be important in different cancer forms, where a growing tumour is
dependent on vascularisation, providing an example of mast cells as “Bad Guys.”
Mast cells in disease –“Bad Guys”
Tumour vascularisation in cancer is one example where mast  cells acts as “Bad
Guys”, however, asthma and allergy are the classical “mast cell-diseases”. Because
of their location in the airway at an interface between the internal and external
environment, the mast  cells  are positioned  to  respond to  exogenous airborne
antigens against which they have been sensitized with specific IgE. However, the
mast cell can also respond directly to nonimmunologic triggers as described in an
earlier  section.  The  preformed  granule  components  that  are  released  upon
stimulation contribute  to  increased vascular  permeability  and  recruitment  of
inflammatory leukocytes as part of both innate and acquired immunity.  Mast cell-
derived mediators and cytokines also contribute to the chronic inflammation of the
asthmatic response. The specific roles of the different  mast  cell  mediators are
reviewed in earlier sections of this thesis.
Lately, mast cells have also been shown to  play an important role in  several
other diseases, most of them autoimmune diseases. Studies on multiple sclerosis
(MS) and its animal model, experimental allergic encephalomyelitis (EAE) were
among the first in this field. MS is a chronic inflammatory disorder that leads to
demyelinization, and a similar disorder can be induced in  rodents by  injecting
different myelin components. The involvement of mast cells in these diseases has
long been suggested (reviewed in Zappulla et al., 2002), and firm proof came in
2000 when it was shown that W/W
v mice develop EAE later and less severely than
control mice (Secor et al., 2000).  Complementation of W/W
v mice with wild type
immature mast cells derived in vitro restores typical EAE susceptibility.
A potential role for  mast  cells  in  rheumatoid arthritis  (RA)  has  also  been
highlighted recently. RA is a chronic  joint  disease characterized by  leukocyte
invasion and synoviocyte activation followed by  cartilage and bone destruction.28
There are several different animal models for this disease and it was shown that
mice lacking mast cells are resistant to  the onset of arthritis in  some of these
models (Malfait et al., 1999, Lee et al., 2002). Furthermore, mast cells accumulate
in the swollen paws of mice suffering from collagen-induced arthritis, and they
degranulate during the disease process (Malfait et  al.,  1999).  Mast  cells  also
accumulate in the synovial tissues  and  fluids  of  humans  suffering from  RA,
further indicating an important role for mast  cells in  this  disease (Crisp et al.,
1984).
Bullous pemphigoid (BP) is an autoimmune skin disease that is  characterized
by  subepidermal  blisters  resulting  from  autoantibodies  against  two
hemidesmosomal antigens, BP230 and BP180. A  mouse model of this  disease
involves the injection of antibodies against BP180 (Liu et al., 1993). Injection of
these antibodies  into  W/W
v  mice  did  not  induce  BP,  but  mice  reconstituted
intradermally with mast cells derived in vitro showed typical features of disease.
Furthermore, it was concluded that the crucial role of mast cells in murine BP is
to recruit neutrophils to the developing lesion. A similar process might also occur
in the human disease, because degranulated mast cells are a prominent feature of
the skin blister of individuals affected with BP (Wintroub et al., 1978).
These are a few examples of physiological and pathological conditions in which
mast cells have been shown to participate. However, considering the large amount
of potent mediators that are released upon activation, combined with the ability of
the mast cell to migrate to different tissues, it is likely that mast cells are involved
in several other processes where inflammation and recruitment of other cells are
key features. Investigations into the mast cell mediators will hopefully help reveal
the biological functions of mast cells.29
Present investigations
Aim
The general aim of this thesis was to investigate how heparin PGs affect mast cell
proteases and their storage and activation. Particular attention was paid to  mast
cell CPA, a mast cell protease that has not gained as much attention as chymase
and tryptase. Bone marrow derived mast cells (BMMCs) were used as a model
system. Granular composition and formation, as  well  as  protease storage was
investigated in cells lacking heparin, either due to a mutation in the gene coding
for NDST-2 (NDST-2
-/-) or in the gene coding for the PG core protein SG (SG
-/-).
Furthermore, the heparin-dependent activation of mast cell CPA was investigated.
Results and discussion
Paper I: Altered storage of proteases in mice lacking heparin
Heparin-deficient mice, generated by gene targeting of the heparin biosynthesis
enzyme, NDST-2, display severe mast cell defects, including an absence of stored
mast cell proteases (Forsberg et al., 1999, Humphries et al., 1999). However, the
mechanism behind these observations is not clear. In this study, we investigated
the importance of heparin in mouse bone marrow-derived mast  cells (BMMCs).
As it is difficult to  obtain large numbers of differentiated mast  cells from live
animals, a good alternative source is the culture of bone marrow stem cells grown
in the presence of appropriate cytokines (IL-3 and stem cell factor), which give rise
to a form of immature mast cells
In agreement  with  previous  reports  (Humphries et  al.,  1999),  NDST-2
+/+
BMMCs grown in the presence of IL-3 were shown to contain several mast  cell
proteases, including mMCP-5, -6 and CPA. In contrast, the IL-3-driven BMMCs
from NDST-2
-/- animals showed similar levels of mMCP-6 as in wild type cells,
but a complete lack of mMCP-5 and mature CPA. Further investigations showed
that the wild type BMMCs contain a significant amount of heparin (10% of the
total GAG chains), in addition to  CS,  whereas the NDST-2
-/-  BMMCs  contain
only highly sulphated CS. Although this finding conflicts with previous studies
(Levi-Schaffer et al., 1986, Dayton et al., 1988), it is consistent with our results,
since NDST-2 inactivation only affects heparin biosynthesis and not CS.
Interestingly, the pro-form, but not the active form of CPA could be detected in
the heparin-deficient cells. This indicates that CPA  is  actually translated in  the
NDST-2
-/- cells but is dependent on heparin for subsequent  processing events.
Thus it seems that heparin, but not CS,  is important for the processing of CPA,
although the mechanisms behind this are  unclear. One  possibility  is  that  the
processing protease requires heparin for optimal activity against pro-CPA. The fact
that both mature CPA and mMCP-5  are missing  from the NDST-2
-/-  BMMCs
suggests that these two proteases are interdependent. As previous studies  have
suggested firstly that both these proteins are necessary for degradation of substrate30
and secondly, that they co-localise to the PG-protein macromolecular complex, it
is very possible that they are mutually dependent on one another for their storage
in mast cell granules.  
In conclusion, this study using BMMCs  derived from normal and NDST-2
-/-
mice, shows that the presence of heparin PG is necessary for storage of mMCP-5
and activation of CPA, whereas mMCP-6 is stored and processed also when only
CS PG is present.
Paper II: Regulation of carboxypeptidase A and mMCP-5
The enzyme responsible for processing of pro-CPA into the mature enzyme is
unknown. However, it has been proposed that cleavage of the 94-residue activation
peptide takes place inside mast cell secretory granules (Dikov et al.,  1994,
Springman,  Dikov  and  Serafin,  1995,  Rath-Wolfson,  2001).  As  it  has  been
suggested that cysteine protease activity is responsible for the process (Springman,
Dikov and  Serafin,  1995),  the  influence of  two  particular cysteine proteases,
cathepsins C and S, on the mast cell proteases was investigated here.
Cathepsin S is a cysteine protease with endopeptidase activity which is thought
to play an important role in antigen presentation (Riese et al., 1996). In a previous
study,  it  was  shown  that  the  cysteine  protease  cathepsin  C  (also  called
dipeptidylpeptidase I, DPPI) is  expressed by  mast  cells (Wolters, Laig-Webster
and  Caughey,  2000)  and  it  has  also  been  demonstrated  that  cathepsin  C  is
responsible for the removal of the two-amino acid activation peptide of mast cell
chymases (Wolters et al., 2001). However, as the role of specific cathepsins in
regulating CPA has not been investigated, this issue was investigated here. As in
paper I, BMMCs were used as a model system. BMMCs were obtained from
cathepsin C
-/-, cathepsin  S
-/-  and  corresponding 
+/+  mice.  In  mature BMMCs,
cellular extracts were assayed for CPA activities. The CPA-like activities as
assessed by the substrate, M-2245, were markedly increased in  both  cathepsin
knockouts compared to wild type cells. Western blot  analysis revealed that the
levels of active,  processed CPA  were markedly higher  in  both  the  cathepsin
knockouts, and closely  corresponded to  the  activity  measurements. A  similar
increase was seen in protein levels of the chymase mMCP-5, whereas the tryptase
mMCP-6 was unaffected by  the  knockouts.  However,  in  the  cathepsin  C
-/-
BMMCs, mMCP-5  was only  seen in  its  proform, in  agreement with  previous
findings (Wolters et al., 2001). The mRNA levels were not affected by any of the
knockouts. The reasons behind the increase in CPA and mMCP-5  levels in  the
cathepsin C- and S-deficient BMMCs are not clear. However, one may speculate
that cathepsin C or S is involved in CPA and mMCP-5 turnover or that cathepsin
C or S activate proteases that are involved in  CPA  and mMCP-5  degradation.
These data also lend further support to the hypothesis that CPA and mMCP-5 are
physically associated, and where an increase or decrease in either of the proteases
may lead to an equivalent change in the corresponding binding partner.31
Taken together, the results from this study indicate that neither cathepsin C nor
S are involved in the processing of CPA, but rather that the loss of either causes
an  increase  in  the  levels  of  CPA  and  mMCP-5  according to  an  unknown
mechanism.
Paper III: A role for cathepsin E in the processing of mast cell CPA
The enzyme responsible for CPA activation was investigated in  this  study.  We
took advantage of existing knockout models in which various cathepsins  were
targeted. Previous studies using protease inhibitors have suggested that a cysteine
protease is involved in mast cell CPA activation (Springman, Dikov and Serafin,
1995). The cysteine protease family includes several lysosomal cathepsins, widely
distributed across many species (Turk,  Turk  and  Turk,  2000).  In  addition  to
cysteine  proteases,  the  cathepsin  family  of  proteases  includes  two  aspartic
proteases,  cathepsins  D  and  E.  The  cathepsins  require  a  slightly  acidic
environment for optimal activity, a condition that is prevalent in lysosomes but
also in other cellular compartments such as the secretory granule of mast cells.
In this study, we assessed the role of two specific cysteine proteases, cathepsins
B and L, in the processing of pro-CPA, but  neither of these cysteine proteases
appeared  to  have  any  significant  role.  Together  with  the  results  from  the
investigation reported in paper II, we were thus unable to provide  any  further
evidence of a major role for cysteine proteases in the processing  of  pro-CPA.
Importantly, however,  we  cannot  exclude  an  involvement  of  other  cysteine
proteases. We instead present evidence that the aspartic protease, cathepsin E,  is
involved in the processing of pro-CPA. This conclusion is supported both by in
vivo experiments demonstrating that  pro-CPA  processing is  defective in  mice
lacking cathepsin E and by in vitro experiments in which purified cathepsin E was
found to process recombinant pro-CPA. Interestingly, the knockout  of  another
aspartic protease, cathepsin D, did not affect pro-CPA processing, indicating that
the ability to process pro-CPA is not a general function of aspartic proteases, but
rather a specific property of cathepsin E.  However, the lack of cathepsin E did not
completely inhibit pro-CPA processing, indicating the  involvement  of  another
protease, possibly a cysteine protease, in the process.
Furthermore,  this  study  revealed  for  the  first  time  the  presence  of
immunoreactive cathepsin E in the secretory granules of mast cells. The granular
location of cathepsin E was also strongly supported by  the lack of staining for
cathepsin E in peritoneal cells lacking heparin due to the lack of the enzyme,
NDST-2, which was shown in paper I to lead to defective processing of pro-CPA.
Furthermore, using affinity chromatography, we showed that  cathepsin E  is  a
high-affinity heparin-binding protein and that the interaction is  pH  dependent,
indicating that histidine residues are involved. Indeed, the  model  of  mouse
cathepsin E identified  five  surface-exposed histidine  residues  that  might  be
interesting candidates for heparin binding.  The association of cathepsin E  with
heparin in the mast cell granules may bring cathepsin E and CPA (which is also32
located to the heparin-complex) into close contact, thus promoting the proteolytic
action of cathepsin E on pro-CPA.
To summarize, the present study  strongly suggests a role for cathepsin E  in
processing pro-CPA and that this process occurs in the mast cell granules where
cathepsin E is located in complex with heparin.
Paper IV: Role of serglycin in secretory granule assembly
Mast cell granule release is an important component of  mast  cell-dependent
inflammation and other pathological conditions. It is therefore imperative  to
understand the mechanisms that lead to granular release as well as to define those
that lead to the assembly of secretory granules. Indeed, the processes involved in
mast cell degranulation, in particular the signal transduction pathways, have been
the  subject  of  intense  investigation  (Blank  and  Rivera,  2004).  In  contrast,
strikingly  little  is  known  about  the  actual  formation  of  mast  cell  secretory
granules.
This issue was investigated using BMMCs from mice lacking  the  PG  core
protein, SG (SG
-/-) and its wild type counterpart (SG
+/+). SG
-/- BMMCs,  which are
essentially devoid of all  PGs,  as well as SG
+/+  cells, were analyzed at various
stages of differentiation for morphology as  well  as  for  content,  expression,
processing and cellular location of the granule components. The morphological
characteristics were examined after staining with  May-Grünwald/Giemsa. Young
cultures  of  both  genotypes  displayed  cells  containing  “empty”  (May-
Grünwald/Giemsa negative) vesicles. On further culture, these vesicles disappeared
in both genotypes while May-Grünwald/Giemsa positive cells appeared in cultures
of   SG
+/+ cells, but not SG
-/- cells. These findings suggest that the formation of
secretory vesicles is initiated independently of SG, but  that  metachromatically
stained mature granules are only formed in the presence of SG. Ultrastructural
investigations using transmission electron microscopy revealed the existence of
secretory  granules  in  similar  numbers  in  both  genotypes.    However,  the
morphology of the granules was different; whereas the SG
+/+  granules contained
defined electron-dense core structures the contents of the SG
-/-  granules were of
more amorphous  character, with  no  defined  electron  dense  core.  The  most
plausible interpretation of these morphological findings is that SG  PG  binds  to
and concentrates secretory granule compounds. However, the granules from SG
-/-
cells were still fully capable of undergoing degranulation.
Furthermore, this study indicated  that  the  knockout  of  SG  does  not  affect
cellular differentiation into mast cells in terms of expression of mast cell markers
at mRNA levels. However, when the protein levels of mast  cell proteases were
investigated, it was found that mMCP-5 was not detected at any time point in SG
-
/- cells and that the levels of mMCP-6 were clearly reduced. Total CPA  antigen
was present in approximately equal amounts in  both  SG
-/-  and SG
+/+  cells, but
only the pro-form was detected in SG
-/- cells, as expected  in  the  light  of  its
dependence on heparin for its activation  (as  showed  in  paper I  and  III).  The33
proteases could still be released upon degranulation, supporting their location in
secretory granules even in the absence of SG. We also demonstrated that histamine
and β-hexosaminidase are released to the same  extent  by  BMMCs  of  both
genotypes. Together, these data clearly indicate that the intracellular transport of
the studied compounds into secretory granules occurs independently of SG  PG.
Furthermore, our results suggest that mMCP-5 is targeted to  degradation if  not
retained in the granules by SG PG whereas mMCP-6 and possibly CPA seem to
be secreted from the cells in the absence of SG PG.
Taken together, our results are consistent with a sorting-by-retention-model of
secretory granule maturation in which SG PG is essential for retention of certain
granule constituents, including selected  proteases  and  histamine,  but  is  not
essential for retention of others, such as β-hexosaminidase.34
Concluding remarks and perspectives
Mast cells are important players in different inflammatory conditions as well as in
host defence against bacteria and parasites. A prominent feature of mast  cells is
their densely packed secretory granules, from which a number of potent mediators
are released upon stimulation. Among these mediators are the mast cell proteases
that constitute up to 35 % of the granular content. However, the biological roles of
these proteases are still largely unknown, and it is therefore difficult to understand
precisely how they  contribute to  mast  cell  function.  More  knowledge of  the
proteases, their properties, how they are stored in the mast cell granules as well as
identification of their biological substrates should help us improve the treatment
of mast cell-related conditions as well as improve our understanding of  the
beneficial roles of mast cells.
The investigations reported in this thesis have mainly focused on the mast cell
protease, CPA, its heparin-dependent activation and storage in mast cell granules
as well as co-operation with the chymase, mMCP-5. Furthermore, the influence of
a number of cathepsins on mast cell proteases has been investigated as well as the
mechanisms for granule formation in mast cells. We have presented evidence for a
heparin-dependent activation of pro-CPA and further showed that this activation is
performed by the aspartic protease cathepsin E.  The finding that cathepsin E  is
localized in the secretory granules of mast cells in a complex with heparin is new
and it may be expected that additional functions will be ascribed to cathepsin E
activity in mast cells. The existence of mice devoid of cathepsin E  offers great
possibilities for further investigations on the involvement of this aspartic protease
in mast cell-related conditions.
Even though the studies included in this thesis have clarified a number of issues
concerning mast cell CPA, the full range  of  its  biological  functions  are still
unknown. From the studies presented here and elsewhere it is likely that CPA acts
in concert with mast cell chymase, and possibly also other mast cell proteases. It
is possible that more substrates will be found that that are open to cleavage  by the
cooperative action of this enzyme pair. However,  the  most  successful way  to
elucidate the role of mast cell CPA in physiological and pathological conditions
will probably be to use the newly constructed CPA knockout mouse strain. Using
this strain in mouse models for different diseases will  be a very powerful tool,
although it should be taken into consideration that this knockout strain also lacks
mMCP-5. Even though previous research has mainly focused on the roles of mast
cell chymase and tryptase, it is very likely that CPA will be proven to  play an
important role in mast cell-related conditions. More knowledge of the structure,
activation mechanisms and biological functions of mast cell CPA may well
increase our opportunities to treat the many conditions in  which mast  cells are
involved.35
Populärvetenskaplig sammanfattning
Varje  dag  stöter  vår  kropp  på  en  stor  mängd  bakterier,  virus  och  andra
sjukdomsalstrande partiklar. Vår hud och våra slemhinnor fungerar som en första
barriär, men många sjukdomsalstrande partiklar kommer ändå in i vår kropp. Dock
är det en väldigt liten del av dessa som faktiskt gör oss sjuka. Detta har vi vårt
immunförsvar att tacka för. Immunförsvaret består av en rad olika celler som  på
olika sätt oskadliggör de bakterier och virus som kommit in i vår kropp. En  av
dessa celler är mastcellen. Mastceller är en typ av immunologiska celler med en
mängd funktioner i vårt försvar mot bakterier och parasiter. Förutom att hjälpa till
att försvara oss mot sjukdomsalstrande partiklar är mastceller även involverade i
olika typer av sjukdomstillstånd. Främst tänker man här på astma och olika typer
av  allergier,  men  även  i  andra  autoimmuna  sjukdomar  som  reumatism  och
multipel skleros (ms) har det visat sig att mastceller är ivolverade.
Det som gör mastcellerna så speciella är dess sekretoriska granula (små korn
inuti cellen) som innehåller en stor mängd inflammatoriska mediatorer (typ av
molekyler). Vid mastcellsaktivering (tex vid parasitangrepp  eller  en  allergisk
reaktion)  släpper  dessa  granula  sitt  innehåll  ut  i  omgivningen  där  de
inflammatoriska mediatorerna kan utföra sina olika uppgifter. Det finns en stor
mängd olika mediatorer i mastcellsgranula, varav den mest kända är  histamin.
Histamin är involverat i allergiska reaktioner där det ger klassiska allergiska
symptom såsom  nysningar och kliande. Andra mastcellsmediatorer är cytokiner
som fungerar som signalmolekyler för andra celler; de signalerar till dessa celler att
det är dags att komma till platsen för tex ett parasitangrepp eller allergisk reaktion
för att hjälpa till. I mastcellsgranula finns dessutom proteaser och proteoglykaner,
vilka har studerats närmare i denna avhandling. En  proteoglykan är en molekyl
som består av en proteinkärna med sockerkedjor på sig. I mastceller finns det två
olika typer av proteoglykaner; heparin och kondrotinsulfat. Det som skiljer dessa
åt är deras sockerkedjor, som är något mer negativt laddade i heparin jämfört med
kondrotinsulfat. Dessa proteoglykaner har en  mängd  olika  roller  i  mastcellen.
Bland annat hjälper de till att lagra övriga mastcellsmediatorer, som  ofta har en
positiv laddning och därmed binder till de negativt laddade  sockerkedjorna på
proteoglykanerna. I den här avhandlingen har förhållandet mellan proteoglykaner
och några andra mastcellsmediatorer, främst proteaser undersökts.
Proteaser är en typ av molekyler som kan  klippa  sönder  andra molekyler i
kroppen. Mastcellsgranula innehåller  tre  huvudtyper  av  proteaser:  tryptaser,
kymaser  och  karboxypeptidas  A  (CPA).  Dessa  proteaser  har  olika
klyvningsspecificitet, dvs de kan klippa i  olika typer av molekyler. Genom att
klippa i olika molekyler kan proteaserna hjälpa till att aktivera dem samt bryta ner
vävnader i kroppen där det kan behövas. I den här avhandlingen har vi  främst
studerat proteaset CPA, som det tidigare inte har funnits så mycket kunskap om.
Genom att använda oss av s.k.  knockout-teknik har vi  studerat hur mastcell-
CPA  interagerar  med  bland  annat  heparin,  hur  CPA  aktiveras  samt  hur
mastcellsgranula bildas. Knockout-teknik går ut på att man förstör genen för en36
viss molekyl, och därmed får möss som saknar den  speciella molekylen,  s.k.
knockout-möss. I den första studien (artikel I) i denna avhandling använde vi oss
av knockout-möss som saknar heparin. Från dessa odlade vi fram mastceller och
studerade hur mastcellsproteaserna uppför sig i frånvaro av heparin. Vi  visar att
vissa  av  proteaserna uppför  sig  helt  normalt  även  utan  heparin  (men  med
kondrotinsulfat) medan mastcells-CPA inte  kan  aktiveras utan  heparin.  Denna
aktivering sker genom att ett annat proteas klipper bort en bit av det inaktiva
CPA, så att det får sin rätta form och kan klippa andra molekyler efter utsläppning
ur mastcellsgranula.
Vidare visar vi (artikel III) att denna aktivering av CPA sker av ett annat proteas
som heter cathepsin E. Däremot har två andra närbesläktade proteaser, cathepsin C
och cathepsin S  ingen  inverkan på  CPA-aktiveringen (artikel II).  Snarare gör
frånvaron av dessa proteaser (pga knockout) att nivåerna av CPA ökar, något som
kan bero på att dessa proteaser vanligtvis bryter ned CPA. Vidare visar vi att
cathepsin E finns i mastcellsgranula där det är starkt bundet till  heparin, vilket
även CPA är. Detta gör troligtvis att cathepsin E kan komma nära CPA och att
CPA-aktiveringen mha cathepsin E sker innuti mastcellsgranula.
I avhandlingens sista studie (artikel IV) använde vi oss av  en  knockout  för
mastcellsproteoglykanernas kärnprotein, serglycin. När denna molekyl inte finns
har mastcellerna i princip inga proteoglykaner överhuvudtaget. Detta leder till att
mastcellsgranula är svårt deformerade eftersom proteoglykanerna behövs för lagring
samt aktivering av flera av de andra mastcellsmediatorerna. Med hjälp av denna
serglycin-knockout  undersökte  vi  hur  frånvaron  av  proteoglykaner  påverkar
bildningen av mastcellsgranula. Vi visar här att trots att granula i mastceller som
saknar proteoglykaner inte kan ses med vanliga färgningsmetoder ändå finns, då de
kan ses klart och tydligt mha elektronmikroskopi. Dock ser de inte likadana ut
som granula från normala mastceller, och de har mycket låga nivåer av de olika
mastcellsproteaserna. När det gäller CPA kunde vi bara se inaktivt CPA,  vilket
stämmer bra med våra tidigare observationer där vi visat att aktivering av CPA är
beroende av heparin. För att ta reda på vad som händer med proteaserna i frånvaro
av proteoglykaner undersökte vi några olika möjliga scenarion. Våra studier visar
att några av mastcellsproteaserna utsöndras från cellen i frånvaro av proteoglykan,
medan andra däremot bryts ned någon av cellens ”avfallskvarnar”, där oönskade
molekyler  förstörs.  Sammantaget  visar  denna  studie  att  funktionella
mastcellsgranula kan bildas utan proteoglykaner, men att  dess innehåll inte kan
hållas kvar på ett korrekt sätt.
Eftersom mastceller är  viktiga  både  i  vårt  försvar  mot  sjukdomsalstrande
partiklar samt i olika typer av sjukdomar så är det mycket viktigt  att  vi  vet så
mycket som möjligt om dessa celler. Mastcellens främsta kännetecken  är  dess
granula som utsöndrar en rad olika mastcellsmediatorer. I den här avhandlingen har
vi  studerat  hur  några  av  dessa  mediatorer,  proteoglykaner  och  proteaser,
sammarbetar och fungerar, samt  undersökt hur mastcellsgranula bildas.  Detta är
viktig information som kan leda till att vi når en högre förståelse om mastceller
och  därmed  kan  förstå  hur  man  tex  bättre  kan  behandla  astma  och  andra37
mastcellsberoende sjukdomar. Det finns mycket kvar att göra innan vi helt förstår
mastcellen, men med denna avhandling har vi tagit ännu ett steg i rätt riktning.38
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